Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Xencor, Inc.
Incyte Corporation
Calithera Biosciences, Inc
AbbVie
AbbVie
Incyte Corporation
Incyte Corporation
Stanford University
Bayer